Alerts will be sent to your verified email
Verify Email
VENMAX
|
Venmax Drugs&Pharma
|
Rekvina Laboratories
|
Cian Healthcare
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
1.17 % | 9.93 % | 1.01 % |
|
5yr average Equity Multiplier
|
0.08 | 6.31 | 3.21 |
|
5yr Average Asset Turnover Ratio
|
0.14 | 0.0 | 0.39 |
|
5yr Avg Net Profit Margin
|
-19.62 % | 0.0 | -17.41 % |
|
Price to Book
|
1.49 | 0.0 | 0.0 |
|
P/E
|
85.63 | 0.0 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
288.55 Days | 0.0 | 55.28 Days |
|
Inventory Days
|
5.2 Days | 0.0 | 219.95 Days |
|
Days Receivable
|
430.69 Days | 0.0 | 224.43 Days |
|
Days Payable
|
141.12 Days | 0.0 | 542.88 Days |
|
5yr Average Interest Coverage Ratio
|
-260.56 | -132.32 | -0.81 |
|
5yr Avg ROCE
|
-47.43 % | -100.9 % | -0.26 % |
|
5yr Avg Operating Profit Margin
|
-65.91 % | 0.0 | 7.22 % |
|
5 yr average Debt to Equity
|
-0.45 | -0.19 | 1.21 |
|
5yr CAGR Net Profit
|
-42.57 % | 18.47 % | n/a |
|
5yr Average Return on Assets
|
199.45 % | -132.46 % | -3.63 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
13.8 % | 41.3 % | 95.0 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-9.33 % | 0.0 | 28.74 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Venmax Drugs&Pharma
|
Rekvina Laboratories
|
Cian Healthcare
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|